Looking for a clinical trial? BreastCancerTrials.org (BCT) recently launched an upgraded version of Metastatic Trial Search (MTS) with improved search and filtering options. Now patients have even more customizable options for finding clinical trials. BCT also just launched Metastatic Trial Talk (MTT), a new companion application that provides patients with carefully selected news and features about metastatic breast cancer research.
Susan G. Komen® Chicago held their first MBC Conference March 8, 2018 with about 200 individuals attending in person or via livestream. The conference included a keynote address from Komen Scholar and Johns Hopkins researcher Dr. Ben Ho Park with breakouts on TNBC, ER+ and HER2+ MBC; a MBC patient panel discussion and Q&A session.
SHARE is working with a focus group of women living with metastatic disease to create an app that will help them identify their treatment goals and help their doctors better understand who they are as people. Stay tuned for its release later this year!
Researchers in clinical oncology and other domains generally focus on results encompassing a statistical mean with little attention to patients undergoing investigational or standard therapies who respond considerably better or worse than the norm.
What proportion of MBC patients are de novo vs recurrent? Currently, the Surveillance, Epidemiology and End Results Program, or SEER, provides extensive information regarding cancer diagnosis and some data regarding primary treatment and survival, but it does not collect information on metastatic cancer recurrence.